SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001493152-24-017001
Filing Date
2024-04-29
Accepted
2024-04-29 16:30:25
Documents
17
Period of Report
2023-12-31

Document Format Files

Seq Description Document Type Size
1 form10-ka.htm   iXBRL 10-K/A 430565
2 ex31-1.htm EX-31.1 18537
3 ex31-2.htm EX-31.2 18441
4 form10-ka_001.jpg GRAPHIC 27723
5 form10-ka_002.jpg GRAPHIC 28538
  Complete submission text file 0001493152-24-017001.txt   885414

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE prph-20231231.xsd EX-101.SCH 3027
7 XBRL LABEL FILE prph-20231231_lab.xml EX-101.LAB 36884
8 XBRL PRESENTATION FILE prph-20231231_pre.xml EX-101.PRE 24154
20 EXTRACTED XBRL INSTANCE DOCUMENT form10-ka_htm.xml XML 7954
Mailing Address 711 STEWART AVE, SUITE 200 GARDEN CITY NEW YORK NY 11530
Business Address 711 STEWART AVE, SUITE 200 GARDEN CITY NEW YORK NY 11530 (215) 345-0919
ProPhase Labs, Inc. (Filer) CIK: 0000868278 (see all company filings)

IRS No.: 232577138 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 000-21617 | Film No.: 24891448
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)